Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation

APPROVED_FOR_MARKETING

Conditions studied: Non Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Breast Cancer, Pancreatic Cancer, Papillary Thyroid Cancer, Other Solid Tumors With Evidence of Activating RET Alteration

In brief

Expanded access for participants with cancer with RET activation who are ineligible for an ongoing selpercatinib (also known as LOXO-292) clinical trial or have other considerations that prevent access to selpercatinib through an existing clinical trial. The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program.

Key facts

Study ID

NCT03906331

Run by

Eli Lilly and Company

Last updated by the study team

2025-01-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of cancer with RET activation, who are not eligible for an ongoing selpercatinib clinical trial and are medically suitable for treatment with selpercatinib
• Have progressed or are intolerant to standard therapy, or no standard therapy option exists, or in the opinion of the investigator, are unlikely to derive significant clinical benefit from standard therapy
• Have adequate organ function

You may not qualify if…

• Currently enrolled in an ongoing clinical study of selpercatinib or another RET inhibitor
• Clinically significant active cardiovascular disease or history of myocardial infarction within 6 months prior to study treatment; ongoing cardiomyopathy; or current prolongation of the QT interval corrected for heart rate using Fridericia's formula (QTcF) interval greater than 470 milliseconds

Where it is running

• Mayo Clinic of Scottsdale — Scottsdale, Arizona, United States
• City of Hope National Medical Center — Duarte, California, United States
• UCLA Medical Center — Los Angeles, California, United States
• Kaiser Permanente — Oakland, California, United States
• Irvine Medical Center — Orange, California, United States
• University of California - San Diego — San Diego, California, United States
• Univ of California San Francisco — San Francisco, California, United States
• Kaiser Permanente — Santa Clara, California, United States
• Kaiser Permanente Medical Center — Vallejo, California, United States
• Memorial Cancer Institute — Hollywood, Florida, United States
• Mayo Clinic in Florida — Jacksonville, Florida, United States
• Florida Hospital — Orlando, Florida, United States
• Tallahassee Memorial Cancer Center — Tallahassee, Florida, United States
• University Cancer and Blood Center — Athens, Georgia, United States
• Emory University — Atlanta, Georgia, United States
• University of Chicago Medicine-Comprehensive Cancer Center — Chicago, Illinois, United States
• Cancer Treatment Centers of America — Zion, Illinois, United States
• Massachusetts General Hospital — Boston, Massachusetts, United States
• Dana-Farber Cancer Institute — Boston, Massachusetts, United States
• University of Michigan — Ann Arbor, Michigan, United States
• START Midwest — Grand Rapids, Michigan, United States
• Mayo Clinic — Rochester, Minnesota, United States
• Comprehensive Cancer Centers of Nevada — Las Vegas, Nevada, United States
• Memorial Sloan Kettering Cancer Center — New York, New York, United States
• Cancer Treatment Centers of America — Goodyear, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.